Marit van Buuren/LinkedIn
Jan 4, 2025, 17:23
Marit van Buuren: Our work on a personalized, autologous neoantigen-specific T cell therapy
Marit van Buuren, Senior Director of T Cell Immunology and Process Development at BioNTech SE, shared a post on LinkedIn about a recent paper by her and colleagues published in Nature Medicine:
Authors: Marit van Buuren, John Haanen.
“Our work on a personalized, autologous neoantigen-specific T cell therapy was just published in Nature Medicine.
We describe the clinical safety and efficacy data of this first-in-human study and share extensive translational data, offering insight into the underlying neoantigen biology.
This was a huge team effort and I want to thank everyone for their contributions!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 5, 2025, 18:37
Jan 5, 2025, 18:34
Jan 5, 2025, 18:32
Jan 5, 2025, 18:26
Jan 5, 2025, 18:24
Jan 5, 2025, 18:13
Jan 5, 2025, 18:11
Jan 5, 2025, 17:52
Jan 5, 2025, 17:49
Jan 5, 2025, 17:42